Insider Purchases: Inside the Buy
Tag: medtech stocks
👁️ CooperCompanies (COO): Insiders Buy $1.33M at $53–$54 as the Stock Crashes
Three CooperCompanies directors just put $1.33 million of their own money into COO near $53–$54. Add record $273M free cash flow, an expanded $3B buyback authorization and an 11.1× forward P/E—and this beaten-down medtech stock deserves a much closer look. 👁️
🩺 Alphatec (ATEC): CEO’s $1M Buy, Positive Free Cash Flow & an 11% Short-Squeeze Fuse 🦾🦴
Alphatec CEO Pat Miles just put $1.01 million of his own money into ATEC at $8.81. With positive free cash flow, improving EBITDA, Valence robotics and 11% short interest, is this battered spine-medtech stock finally reaching its turnaround moment?
🦴 Enovis (ENOV): CEO Buys the $19 Crash—Is This Falling Knife Finally a Buy? 🤖
Enovis CEO Damien McDonald bought ENOV again after shares collapsed toward $19. Insiders are accumulating, institutions remain heavily invested, analysts see substantial upside and adjusted valuation has fallen below 5x forward earnings. But short interest is high, leverage and integration risks remain—and momentum is dreadful. ENOV may be the ultimate FunStock signal collision.
🫀 Boston Scientific (BSX): A GARP Reset on a Medical Device Powerhouse
Boston Scientific stock has fallen nearly 48% from its highs, but the business engine remains strong. With double-digit revenue growth, major cardiovascular catalysts, director insider buying, low short interest, and a $2B buyback, BSX may be one of the cleaner large-cap healthcare GARP setups on the market.